Search Results for "Neurogenic Detrusor Overactivity"
Original Source: Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) Patients
Background: Although a small group, special attention has to be given to lower urinary tract (LUT) dysfunctions in spinal cord injury (SCI) patients, as they also suffer under a loss of motor-sensory function and autonomic regulation next to the severe deficiencies in bladder and bowel control. Autonomic dysregulation linked with LUT dysfunction can cause autonomic dysreflexia with life threatening increases in blood pressure and there is still no concept for an early rehabilit...
Matching Channels
Matching News
Allergan, Inc. is pleased to announce that BOTOX® has been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the management of urinary incontinence in adult patients with...
Repeated toxin treatment sustains benefits in incontinence patients
Repeated treatment with onabotulinumtoxinA consistently reduces urinary incontinence episodes in patients with neurogenic detrusor overactivity, show findings from an extension study of Phase III tria...
Extra data confirms Northera effectiveness in neurogenic OH, says Chelsea
Chelsea Therapeutics has announced results from an integrated dataset of over 250 patients which showed those with Northera (droxidopa) experienced statistically significant improvements in their symp...
Drug injections helpful in pediatric neurogenic bladder
NEW YORK (Reuters Health) - Endoscopic treatment of neurogenic urinary sphincter insufficiency with dextranomer/hyaluronic acid (Dx/HA) is effective in about half of young patients, according to F...
[Allergan], [American Medical Systems] team up to develop {Botox} using {JetTouch}
[Allergan Inc.] will develop {Botox} (onabotulinumtoxin A) for overactive bladder (OAB) using [Endo Health Solutions Inc.]’s [American Medical Systems Holdings Inc.]’s (urological/gynecological me...
Matching PubMed Articles
BACKGROUND: To present a comprehensive experience of botulinum toxin A (BTX-A) injected into the detrusor muscle in patients with spinal cord injuries (SCI) causing neurogenic detrusor overactivity. M...
To evaluate the effect of a transient receptor potential vanilloid 1 (TRPV1) antagonist GRC 6211 on neurogenic detrusor overactivity (NDO) of spinal origin.
Botulinum toxin treatment for bladder dysfunction.
Botulinum toxin A is available under three different protein complexes that are not interchangeable until appropriate comparative studies are undertaken. The best studied for the treatment of urinary...
Effect of prolapse repair on voiding and bladder overactivity.
PURPOSE OF REVIEW: To determine the effects of repair of pelvic organ prolapse (POP) on detrusor overactivity, overactive bladder (OAB) symptoms and voiding function. Understanding the cause of OAB in...
Botulinum toxin for conditions of the female pelvis.
INTRODUCTION AND HYPOTHESIS: Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overacti...
